logo

Products

Logo

Dhan App

Stock Market App built for Super Traders & Long Term Investors.

Logo

Dhan Web

Web Trading Platform for those who love to trade from the big screen.

Logo

Options Trader App

Option Trading App built especially for India's F&O Traders.

Logo

Options Trader Web

Option Trading Platform to build, analyze, & execute F&O trades.

Logo

Trade from tv.dhan.co

Trade with TradingView Chart features for FREE on tv.dhan.co.

Logo

Connect to TradingView

Connect Dhan to TradingView - Place orders from tradingview.com

Logo

DhanHQ Trading APIs

Trade with Algo, Connect Apps, Build Services using APIs for FREE.

Logo

smallcases on Dhan

Build wealth with smallcase investment for FREE on Dhan.

Logo

Margin Trading Facility

Get 5X Leverage on 1700+ stocks. Trade Now, Pay Later.

Logo

ScanX Stock Screener

50+ Readymade Screeners, Live Market Insights & Instant Trade Execution.

Logo

Rent Stocks via SLBM

Earn up to 35% p.a. over & above your portfolio holdings!

PricingOpen Demat Account at ₹0 AMCBecome a PartnerCustomer ServiceDhan SupportDhan Blog
fuzz
Logo
MadeForTrade CommunityIndicator by Dhan

Download the App Now!

raise
raise
Home
InvestmentsIPOFabtech Technologies IPO

Fabtech Technologies IPO

Mainboard

Open Date

29 Sep 2025

Close Date

1 Oct 2025

Min Investment

₹ 13,575

Max Investment

₹ 5,00,000

Lot Size

75

Issue Size

₹ 230.35 Cr

Price Range

₹ 181 - ₹ 191
status

This IPO is now Live.

Click here for live price
IPO Timeline
check
IPO Offer Start
29 Sep 2025
check
IPO Offer Ends
1 Oct 2025
check
Allotment Finalisation
2 Oct 2025
check
Refund Initialisation
3 Oct 2025
check
Non-Institutional Buyers (sHNI)
3 Oct 2025
check
Listing of Shares
7 Oct 2025
IPO Subscription Details as on 8 Dec 2025, 12:33 AM
Qualified Instituational Buyers (QiB)
2.02 x
Retail
2.02 x
Employees
1.99 x
Non-Institutional Buyer (bHNI)
1.65 x
Non-Institutional Buyer (sHNI)
2.56 x
Note: This information is provided for general guidance only. Dates may be subject to change.
border
About the Company
Fabtech Technologies Limited is a global company headquartered in India, specializing in turnkey engineering solutions for pharmaceuticals, biotech and healthcare companies. The company has a presence spanning more than 62 countries across Middle East, Africa, Asia, Europe, Latin America, North America, and other regions. The company provides extensive technical expertise and infrastructure to deliver comprehensive solutions for establishing aseptic manufacturing facilities, encompassing everything from design to certification. The company offers comprehensive start to finish services in greenfield projects, encompassing disease identification, planning, designing, engineering, procurement, quality assurance, logistics management and installation and commissioning for a wide range of customers across various geographies, particularly key emerging economies. Additionally, the company also offers some of its engineering solutions, which majorly include, equipment procurement and supply and logistics management, on a standalone basis, either as part of greenfield or brownfield projects. The company's comprehensive solutions encompass the entire project lifecycle of customers and address the three key elements in pharmaceuticals, biotech and healthcare facilities, namely, bio clean air, clean water, and process. The company has an established track record in executing pharmaceutical projects across a diverse range of dosage forms, encompassing, liquids, solids, and semisolids. The company is part of Fabtech Group which was established in 1995 and has over twenty-nine years of operating history in executing pharmaceutical turnkey projects. Since incorporation and till July 31, 2025, the company has completed fifty one projects across countries, namely Saudi Arabia, Egypt, Algeria, Bangladesh, Ethiopia, Sri Lanka, United Arab Emirates. The company believes that as on July 31, 2025, it has a strong order book aggregating to ₹ 90,441.87 lakhs.
rocket

Founded In

2018

rocket

CEO

Naushad Alimohmed Panjwani

img

DRHP

img

Financials of Fabtech Technologies IPO

Income Statement
Balance Sheet
Cash Flows
Total Income
Total Expenses
Total Profit
Key Performance IndicatorsMar 2023Mar 2024Mar 2025
Operating Revenue19,379.7522,613.6332,666.85
Other Income611.26446.81927.36
Total Income
19,991.0123,060.4433,594.21
Total Expenses
17,564.9119,621.5629,367.92
Profit Before Tax2,789.873,577.026,043.37
Total Profit
2,173.372,721.744,645.30

All figures are in lakhs (₹)

border

Utilisation of Proceeds

All figures are in lakhs (₹)

PurposeAmount
The company proposes to utilize the Net Proceeds to fund working capital requirements for business operations and executing future projects. The working capital requirement depends on multiple factors including order book value, expected order wins, payment terms with customers and suppliers, and margin money for bank guarantees and letters of credit. The company is required to make upfront advances to third-party equipment suppliers ranging between 10% to 30% of the total purchase order value, and advance payments to third party contractors for installation and commissioning. The company also needs to issue Bank Guarantees upon receiving advance payments from customers and provide performance bank guarantees to secure customers against installation or quality defects. As an asset light company without material collateral, the company is required to place fixed deposits with lenders to secure Bank Guarantees, leading to blockage of liquidity. The funds will be deployed over Fiscals 2026 and 2027 to support the company's expanding operations and meet the growing order book position.12,700
The company intends to pursue inorganic growth initiatives through strategic acquisitions by acquiring manufacturers engaged in manufacturing of process equipment and other critical components in India, United Arab Emirates, Saudi Arabia and Egypt. These acquisitions are aimed at expanding execution capabilities, diversifying customer base, enabling operational integration with the business, cost and process optimization, streamlining business processes, expanding geographic reach and gaining further market share. The company intends to acquire minority stake in four to five target companies to set up manufacturing capabilities in foreign jurisdictions, which would enable execution of projects in such geographies by sourcing key equipment and components domestically through integrated manufacturing capabilities while retaining the asset light model, thus reducing logistical costs and increasing margins. The majority of the Net Proceeds shall be utilized towards funding acquisitions in foreign geographies.3,000
The company proposes to deploy the balance Net Proceeds towards general corporate purposes, subject to such amount not exceeding 25% of the Gross Proceeds, in compliance with the SEBI ICDR Regulations. The general corporate purposes include meeting fund requirements which the company may face in the ordinary course of business, strengthening lead generation capabilities by marketing equipment and solutions, meeting ongoing general corporate contingencies, and business requirements in the ordinary course of business towards salaries and wages, rent, administration expenses, upgrading technology and maintenance, payment to creditors, and advisory services. The allocation or quantum of utilization of funds towards specific purposes will be determined by the Board based on business requirements and other relevant considerations from time to time.-
border
  • Key turnkey engineering solution provider offering integrated engineering solutions with comprehensive service offerings: The company is a key turnkey engineering solution provider in pharmaceuticals capex space, offering comprehensive start to finish solutions encompassing designing, engineering, procurement, installation and testing of pharmaceutical equipment for a wide range of customers. The company provides comprehensive start to finish execution of controlled environment infrastructure with the ability to provide end to end solution encompassing designing, engineering, procurement, installation, testing, commissioning, management and operational support for a wide range of customers primarily in the pharmaceutical, biotechnological, and healthcare sectors across geographies. Since incorporation and till July 31, 2025, the company has completed around fifty one (51) projects, across countries, namely Saudi Arabia, Egypt, Algeria, Bangladesh, Ethiopia, Sri Lanka, United Arab Emirates. During the Fiscal 2025, Fiscal 2024 and Fiscal 2023, the company's order book comprised, thirty-two (32), thirty-six (36) and thirty-eight (38), ongoing as well as completed turnkey projects, representing revenue from turnkey projects of ₹ 24,350.14 lakhs, ₹ 19,560.58 lakhs and ₹ 17,444.66 lakhs, respectively and constituting 74.54% 86.50% and 90.01% of total revenue, for the said Fiscals, respectively. As on July 31, 2025, the company has an order book aggregating to ₹ 90,441.87 lakhs.
  • Asset-light and integrated business model: The company has adopted what it believes to be a scalable, asset-light and less capital-intensive business model by procuring equipment from Related Entities and third party equipment suppliers. Since the company procures majority of the equipment required by customers through Related Entities, on an arms-length basis and third party equipment suppliers, it is not required to make capital investment for setting up a manufacturing unit or heavy machinery for manufacturing the equipment supplied. The company believes that this asset light business model, enables it to direct all efforts towards project execution and sales and marketing activities, while ensuring that the equipment supplied to customers are of desired quality and delivered in a timely manner. During Fiscal 2025, Fiscal 2024 and Fiscal 2023, expenditure incurred towards purchase of equipment through Related Entities was ₹ 5,445.00 lakhs (25.68%), ₹ 4,225.05 lakhs (34.89%) and ₹ 3,769.04 lakhs (36.82%) respectively of total procurement costs.
  • In-house software technology capabilities: The company has developed in-house software technology capabilities that track the complete life-cycle of projects and enable various teams to manage, supervise and control their respective responsibilities in a timely and coordinated manner. All project planning, development, execution and completion activities are connected to the company's central information technology network through 'FabAssure' a project management system facilitating real time monitoring and tracking of projects and enabling faster project execution. The company believes that its in-house technology capabilities enable it to increase operating efficiencies, timely execution of projects, improve service quality and maintain stringent operational control.
  • Diversified order book across geographies, clients, and business verticals: Over the last three years, the company has expanded and diversified its order book, reflecting its commitment to organic and sustainable growth while pursuing a broader range of projects. The company's order book has grown from ₹ 42,464.62 lakhs as of March 31, 2023 to ₹ 61,306.41 lakhs as of March 31, 2024 and ₹ 76,173.60 lakhs as of March 31, 2025. With a broad range of expertise and infrastructure, the company is equipped to deliver a wide array of projects, encompassing granulation solutions, isolator containment systems, injectable projects, encapsulation solutions, water treatment solutions, cleanroom infrastructure development, cleanroom system integration, and cleanroom equipment installation, HVAC, mechanical, electrical and plumbing and packaging lines, among others. The company also has capabilities in executing pharmaceutical projects across all dosage forms, encompassing, liquids, solids, and semisolids.
  • Project execution across diverse and challenging geographies: The company is an enabler in consolidating technical knowhow and infrastructural capabilities for aseptic manufacturing and research processes in the pharmaceutical, healthcare and biotechnology sectors, in key emerging economies like Bangladesh, Egypt, Ethiopia, India, Kenya, Kingdom of Saudi Arabia, Morocco, Nicaragua, Nigeria, South Africa, Turkey, UAE, USA and Tanzania. The company has a track record of executing projects across diverse and challenging geographical landscapes. Owing to its international operations particularly in emerging economies, the company has developed the capabilities of successfully delivering projects in regions where conditions are less than favourable, on account of regional conflicts, disruption in supply chains, difficulty in recruiting skilled employees, etc. The company addresses and mitigates such challenges through risk assessment, comprehensive planning, and leveraging local expertise.
  • Efficient lead funnelling leading to higher mandate conversion: The company undertakes a lead funnelling process for identifying and generating leads from various sources and converting them into opportunities. The company's proposal to order conversion ratio has improved from 7.79% in Fiscal 2023 to 8.98% in Fiscal 2024 and 10.24% in Fiscal 2025. Value of proposals submitted increased from ₹ 3,71,059.98 lakhs in Fiscal 2023 to ₹ 4,49,109.19 lakhs in Fiscal 2024 and ₹ 4,64,950.00 lakhs in Fiscal 2025. Value of orders received increased from ₹ 28,893.67 lakhs in Fiscal 2023 to ₹ 40,350.23 lakhs in Fiscal 2024 and ₹ 47,623.45 lakhs in Fiscal 2025.
  • Track record of executing projects across all dosage forms: The company is engaged in the business of building pharmaceutical, biotech and healthcare capabilities by offering comprehensive start to finish solutions encompassing designing, engineering, procurement, installation and testing of pharmaceutical equipment for a wide range of customers. Owing to its comprehensive service offerings, the company has an established track record in executing pharmaceutical projects across a diverse range of dosage forms, encompassing, liquids, solids, and semisolids. The company's capabilities span the manufacturing of tablets, capsules, liquids injectables, and semisolid forms such as ointments and inhalers. The company specializes in executing projects across broad spectrum of pharmaceutical products, from oncology and cancer drugs to widely-used over-the-counter medications.
  • Experienced Leadership Team with Fabtech Group parentage: The company is led by the Fabtech Group, which has an operating history of more than two decades in India and across geographies. The company leverages the Group's industry expertise and reputation to drive business development and strategic expansion. With a combined experience of over three decades in pharmaceutical engineering, the company's Promoters - Aasif Ahsan Khan, Hemant Mohan Anavkar, and Aarif Ahsan Khan, have been instrumental in shaping the company's success, and growth trajectory. Additionally, the company is led by CEO, Ashwani Kumar Singh who has over three decades of professional experience including with Grasim Industries Limited, Jubilant Organosys Limited, Regent Drugs Limited, Piramal Enterprises Limited and Watson Pharma Private Limited.

Open IPOs for Subscription

No Open IPOs

Stay tuned, there will be more IPOs listing soon!


fuzz

Listed IPOs

No Listed IPOs

Stay tuned, there will be more IPOs listing soon!


Invest & Trade with a Trading
Platform That's #MadeForTrade

Open your Dhan Account in minutes!
Start Now
border
logo

Join our Community

community logo

Follow us on

twitter
telegram
Linkedin
youtube
instagram
facebook

built with love
for Indians who love to invest & trade

raise

We are part of Raise Financial Services

raise
raise

Explore  |  Sitemap


*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

We are doing so by giving you access to not just one but 6 products within the Dhan ecosystem:


This means that with Dhan, you'll be able to start:


Lakhs of users already trust Dhan for their online stock trading and investing needs. Dhan is growing rapidly because of the love we receive from SuperTraders and Long-Term Investors who acknowledge that the platform is innovating for them, building super useful features that help them do everything from investing in stock market to trading F&O like a pro on the Tradingview charts and much more.

While we are growing, we will always remember why we started building in the first place - you. Our user-first approach will always be at the heart of our philosophy. Come join us on this incredible journey!

Try it out, you can close your account at anytime using this link.

©2021-2025 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered & Corporate Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104, Customer Care: 9987761000.

Details of client bank account

For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. Issued in the interest of the investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | Investor Charter for Research Analyst | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details |
MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Grievances RA | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors